Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & Bristol Myers Squibb

7 shared events · Importance 3 · Last updated Sep 01, 2026

Importance
3
Shared Events
7
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
57
Business
United States — Food and Drug Administration: The US FDA provides supportive regulatory frameworks that facilitate product approvals and market growth in North America.
Bristol Myers Squibb: Bristol Myers Squibb is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
32
Regulatory
United States — Food and Drug Administration: Published the Complete Response Letter rejecting Replimune's BLA and earlier briefing documents questioning the IGNYTE study data, triggering the share decline that underpins the lawsuits.
Bristol Myers Squibb: Its PD-1 inhibitor Opdivo was the combination partner in the rejected RP1 BLA; the rejection is a minor setback to one combination program within a large diversified portfolio.
Jul 29, 2026 · 139 articles
32
Regulatory
United States — Food and Drug Administration: The FDA granted expedited approval to daraxonrasib, marking a regulatory milestone and demonstrating its commitment to accelerating cancer treatments. The approval was issued 6.5 months ahead of schedule, reflecting the agency's priority review process.
Bristol Myers Squibb: Bristol Myers Squibb, another KRAS inhibitor developer, is similarly affected by the competitive landscape.
Aug 26, 2026 · 92 articles
23
Business
United States — Food and Drug Administration: Reportedly rejected ITM-11's application over third-party manufacturing issues and approved Telix's Pixclara and Curium's Bexlutry; its approvals gate up to $250 million in milestone payments.
Bristol Myers Squibb: Cited as a recent acquirer of radiopharmaceutical assets, part of the broader M&A trend in the industry.
Sep 21, 2026 · 6 articles
12
Business
United States — Food and Drug Administration: The FDA declined to approve Lantheus' LNTH-2501 application due to manufacturing issues, a setback for Lantheus' pipeline.
Bristol Myers Squibb: Bristol Myers Squibb is mentioned as a prior acquirer in the sector, highlighting the trend of radiopharmaceutical consolidation.
Aug 03, 2026 · 7 articles
0
Tech
Bristol Myers Squibb: Bristol Myers Squibb is jointly developing pumitamig with BioNTech, which is being used in the clinical trial collaboration with Boehringer Ingelheim.
Apr 09, 2026 · 6 articles
0
Business
Apr 27, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and Bristol Myers Squibb interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.